Contractile Gastrointestinal Organoid System for Pathogen Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying gastrointestinal diseases and pathogen interactions lack fully functional, contractile gastrointestinal organoids derived from human induced pluripotent stem cells (HiPSCs that mimic the natural human intestinal microbiome and physiological behavior, requiring extended time and being non-cost-effective.
Innovation Solution
Development of a method to generate fully functional, contractile gastrointestinal organoids from HiPSC-derived 3D gut spheroids using Activin A, Wnt3A, and FGF4, which are then seeded on a gel matrix dome within an electroconductive plate for rapid screening of pathogens and drugs, allowing for the maintenance of a complete microbiome system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to generate gastrointestinal organoids, then the organoids can be produced, but the process requires extended time (over 30 days) and is not cost-effective
Solution Approach 1:
The patent applies preliminary action by pre-differentiating HiPSCs into gut spheroids with specific patterning (villi and crypts) before seeding them on the gel matrix dome. This pre-organization of cellular structures accelerates subsequent maturation, reducing the total time to achieve mature intestinal phenotypes from over 30 days to 18 days.
Solution Approach 2:
The patent employs parameter changes by optimizing culture conditions including specific growth factors (Activin A, Wnt3A, FGF4, Rspondin, Noggin, EGF), media composition, and oxygen tension to accelerate organoid development. These parameter optimizations enable faster maturation while maintaining physiological relevance.
2Reliability
If fully functional contractile gastrointestinal organoids with complete microbiome are generated, then the system accurately mimics human physiology, but the complexity of the system increases
Solution Approach 1:
The patent applies segmentation by dividing the gastrointestinal system into distinct functional components: epithelial cells, endothelial cells, mesenchymal cells, and a complete microbiome system. Each component is cultured and differentiated separately before being integrated, allowing for controlled complexity while achieving physiological accuracy.
Solution Approach 2:
The patent uses composite materials by combining multiple cell types (epithelial, endothelial, mesenchymal) with a gel matrix dome and microbiome to create a composite organoid system. This composite structure achieves physiological complexity while maintaining organizational clarity through defined layers and zones.
3Reliability
If contractile behavior is achieved in reproducible organoids, then the system accurately recapitulates human intestinal physiology, but the difficulty of generating such organoids increases
Solution Approach 1:
The patent uses an intermediary approach by introducing a gel matrix dome as a supportive scaffold that facilitates the development of contractile behavior. The gel matrix provides mechanical support and signaling cues that enable smooth muscle cell differentiation and organization, making contractile behavior achievable in reproducible organoids.
Solution Approach 2:
The patent applies self-service by allowing organoids to spontaneously develop contractile behavior through self-organization of smooth muscle cells and enteric nervous system components. The culture system provides necessary growth factors and conditions, but the actual contractile functionality emerges autonomously from the organoid structure itself.
Data Source
AI summary
A gastrointestinal organoid provides a fully functional complex GIO consisting of epithelial, endothelial, and mesenchymal cells with the microbiome of a natural human gastrointestinal system and exhibiting contractile behavior, useful for the rapid and sensitive screening of pathogens, toxins, drugs, environmental factors, and other compounds or diseases.